Combination of Copeptin and Troponin Assays to Rapidly Rule Out Non‐ST Elevation Myocardial Infarction in the Emergency Department

Charpentier, Sandrine; Maupas-Schwalm, Françoise; Cournot, Maxime; Elbaz, Meyer; Botella, Jean Marie; Lauque, D.

doi:10.1111/j.1553-2712.2012.01350.x

Cited by 34 publications

(37 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results were in accordance with Reichlin et al, Keller et al, Charpentier et al and Folli et al where copeptin levels at admission were higher in the AMI group presenting zero to four hours after onset of symptoms with a falling pattern afterward from five to ten hours [29][30][31][32].…”

Section: Discussionsupporting

confidence: 82%

The Clinical Value of Copeptin in Acute Coronary Syndrome

Aborehab¹

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

Abstract(1) The introduction of a novel immunoassay measuring copeptin, the c-terminal part of the vasopressin prohormone provided a unique window in common medical disorder. We examined the ability of copeptin in combination with cardiac troponin-I (cTn-I) in diagnosis of AMI, the differentiation between AMI and UA and finally evaluate the ability of copeptin in enhancing sensitivity of cTn-I at early hours of admission in emergency department.(2) This study was carried on 50 subjects; they were divided into 33 patients with AMI and 17 patients with UA. Concentrations of copeptin, cTn-I and CK-MB were determined in their sera.(3) In AMI group, the mean serum level of copeptin was highly significant in three hours than admission time and six hours. The mean serum level of cTn-I was highly significant in six hours than the admission time and three hours. The sensitivity and specificity of copeptin and cTn-I combination were 100% and 100% at the admission time versus 72.7% and 82.4% with cTn-I alone also versus 97% and 94.1% with combination of cTn-I and CK-MB. The AUC of the combination of copeptin and cTn-I was 1 which was significantly higher than the AUC of cTn-I alone 0.81 and the AUC of combination of cTn-I and CK-MB 0.92 (4) Copeptin as a single marker has diagnostic value being superior to cTn-I within the first three hours after acute chest pain. Dual marker strategy combining cTn-I and copeptin show incremental value in the early rule out of AMI.

show abstract

Section: Discussionsupporting

confidence: 82%

The Clinical Value of Copeptin in Acute Coronary Syndrome

Aborehab¹

2013

J Clin Exp Cardiolog

View full text Add to dashboard Cite

show abstract

“…Several other studies with conventional cTn assays support the conclusions of the two studies. Again the NPV is increased, but does not reach 100 % [28,29].…”

Section: Copeptinmentioning

confidence: 98%

Laboratory diagnostics of myocardial infarction – troponins and beyond

Lackner

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

In the case of suspected acute coronary syndrome and myocardial infarction positive diagnosis or exclusion strongly depend on the use of biomarkers and in particular cardiac troponins (cTn). Especially in the early phase of myocardial infarction the sensitivity of cTn assays has been unsatisfactory. This has led to the investigation of many other potential markers for the early diagnosis of myocardial infarction. In addition, several traditional markers have been advocated, e.g., myoglobin, as these were considered to be more sensitive than cTn. With the advent of high-sensitive (hs) cTn assays the value and practical use of the alternative or additional markers has to be reassessed. According to the currently available data, no single marker is superior to hs-cTn for the diagnosis of acute myocardial infarction. In particular, the notion of superior sensitivity of myoglobin compared to cTn no longer holds true. There are two protein markers, hearttype fatty acid binding protein and copeptin, and plasma free fatty acids that may increase the diagnostic value and specifically the negative predictive value when determined on admission in combination with hs-cTn. However, the incremental gain, if any, is small. Further data are needed to determine, whether these markers can in fact improve diagnosis and if they are superior to the recommended use of the relative or absolute change of hs-cTn after 3 h.

show abstract

“…Повсеместная распространенность, часто непред сказуемый исход и отсутствие четких прогностиче ских критериев обеспечивают острому коронарному синдрому (ОКС) одно из центральных мест в реестре наиболее актуальных проблем здравоохранения во всем мире [1]. Прогноз больных, госпитализирован ных с подозрением на ОКС, в высокой степени опре деляется тем, насколько своевременно поставлен диагноз и начато адекватное лечение.…”

Section: актуальностьunclassified